VA
LEGN icon

Vident Advisory’s Legend Biotech LEGN Stock Holding History

Vident Advisory’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17,464
Closed -$568K – 1602
2024
Q4 		$568K Sell
17,464
-5,573
-24% -$231K 0.01% 879
2024
Q3 		$1.12M Buy
23,037
+10,616
+85% +$565K 0.03% 593
2024
Q2 		$550K Sell
12,421
-4,001
-24% -$185K 0.02% 829
2024
Q1 		$921K Buy
16,422
+4,686
+40% +$283K 0.02% 604
2023
Q4 		$706K Sell
11,736
-534
-4% -$33.8K 0.02% 660
2023
Q3 		$824K Buy
+12,270
New +$852K 0.03% 564

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vident Advisory's LEGN Position: Q1 2025 in Review

Vident Advisory sold out of Legend Biotech (LEGN) in Q1 2025, closing a stake of 17,464 shares — an estimated $568K sold.

Vident Advisory first reported a position in LEGN in Q3 2023 and held it in 6 quarters. The position peaked at $1.12M in Q3 2024. 208 funds tracked by Wall St. Rank hold LEGN as of Q1 2025.

  • Vident Advisory reported no remaining Legend Biotech position as of Q1 2025 after selling out during the quarter.
  • Vident Advisory sold 17,464 Legend Biotech shares in Q1 2025, an estimated $568K.
  • Vident Advisory first reported a position in Legend Biotech in Q3 2023 and held it in 6 quarters.
  • Vident Advisory's Legend Biotech position peaked at $1.12M in Q3 2024.
  • 208 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2025.

Based on Vident Advisory's 13F filing for Q1 2025, filed 15 May 2025.